Intercept Pharmaceuticals Inc.
Morristown, NJ
- UEI
- GHNKCLBJRMK7
- CAGE
- 7MWA6
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 305 Madison Ave, Morristown, NJ 07960, USA
- Website
- interceptpharma.com
- Founded
- 2002
- Employees
- 251-1K
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Acer Therapeutics Inc. | Boston, MA | 456110 Pharmacies and Drug Retailers |
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Idorsia Pharmaceuticals US Inc. | Wayne, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Mylan Pharmaceuticals Inc. | Morgantown, WV | 325412 Pharmaceutical Preparation Manufacturing |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Intercept Pharmaceuticals Inc., doing business as Intercept, is a corporate entity registered in SAM.gov to receive prime contract awards from the federal government. As a for-profit organization, Intercept specializes in providing pharmaceutical products to federal agencies.
Intercept has received several prime federal contract awards from the Department of Veterans Affairs for the supply of its drug Ocaliva. These awards include delivery orders and blanket purchase agreement (BPA) calls for the procurement of Ocaliva 5mg tablets. The contracts were awarded through the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and did not involve any set-asides. The agencies that awarded these contracts include the Veterans Health Administration's Veterans Integrated Service Networks 7 and 9. The contracts aimed to fulfill the treatment needs of veterans suffering from primary biliary cholangitis, a chronic liver disease for which Ocaliva is an approved treatment.
Intercept currently holds a Blanket Purchase Agreement (BPA) with the Department of Veterans Affairs National Acquisition Center for the supply of Ocaliva. This single-award BPA, awarded on January 25, 2022, has a potential value of $15 million and a period of performance through January 24, 2025. The BPA falls under the Pharmaceuticals and Drugs Federal Supply Schedule and provides an efficient means for the Department of Veterans Affairs to procure Ocaliva for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid for veterans who have an inadequate response to the latter drug alone. As the sole awardee, Intercept Pharmaceuticals Inc. will supply Ocaliva to the agency through this Indefinite Delivery Vehicle contract vehicle.
Quick answers
Is Intercept Pharmaceuticals Inc. registered in SAM.gov?
Yes. Intercept Pharmaceuticals Inc.'s SAM.gov registration is active through October 17, 2026.
Which contract vehicles does Intercept Pharmaceuticals Inc. hold?
Intercept Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Intercept Pharmaceuticals Inc.'s most recent federal award?
Intercept Pharmaceuticals Inc.'s most recent federal contract award is Ocaliva 5MG (36C24920F0531), from Veterans Integrated Service Network 9 (VHA), on September 14, 2020.
On GovTribe
See Intercept Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors